Ποια είναι η τιμή για Mithra Pharmaceuticals S.A. (MITRA)

Η τιμή για Mithra Pharmaceuticals S.A. (MITRA) είναι $0.25620952

Ποια είναι η κεφαλαιοποίηση αγοράς για Mithra Pharmaceuticals S.A. (MITRA)

Η κεφαλαιοποίηση αγοράς για Mithra Pharmaceuticals S.A. (MITRA) είναι $17.14M

Mithra Pharmaceuticals S.A. (MITRA) Τιμή και Κεφαλαιοποίηση Αγοράς

Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège, Belgium, specializes in the creation, production, and worldwide commercialization of advanced therapeutic solutions. The company's core focus areas include contraception, the management of menopause, and treatments for hormone-dependent cancers. Its robust development pipeline features Estelle, a combined oral contraceptive that has successfully concluded Phase III clinical trials, and Donesta, an estetrol-based oral hormone treatment currently undergoing Phase III development for menopausal symptoms. Mithra's product portfolio also encompasses Myring, a hormonal contraceptive vaginal ring; Tibelia, a therapy designed to address both menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant targeting prostate and breast cancers, as well as various benign gynecological conditions. Furthermore, the company markets NEXTSTELLIS, an established oral contraceptive pill. Their offerings span diverse pharmaceutical formats, including polymeric devices, implants, sterile injectable medications, and hormonal tablets.

Η τιμή για MITRA	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$79,311.10 $17.14M	NVDA	$5.307T	+30,955,462.62%
$68,014.33 $17.14M	AAPL	$4.551T	+26,546,272.84%
$62,090.29 $17.14M	GOOG	$4.154T	+24,234,085.87%
$53,633.71 $17.14M	MSFT	$3.589T	+20,933,433.75%
$41,801.12 $17.14M	AMZN	$2.797T	+16,315,108.86%

Η τιμή για MITRA

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$79,311.10 $17.14M